IsoPlexis: Siddhartha Kadia
Siddhartha Kadia has joined the board of directors of single-cell proteomics firm IsoPlexis. Previously, he was president of the life sciences division at Life Technologies; president and CEO of EAG Laboratories; and corporate VP at Invitrogen. He also serves as director of NuVasive, ALS, Applied Technical Services (ATS), and BioSkryb Genomics. Kadia holds a master's degree from Rutgers University and a Ph.D. in biomedical engineering from Johns Hopkins University.
Centogene: Rene Just
Rene Just has been appointed as CFO of Centogene, effective June 1. He will succeed Richard Stoffelen, who will remain with the company until June 30 to facilitate the transition. Just joins Centogene from Riemser Pharma Holding, where he was group CFO. Previously, he held finance positions in public and private companies in pharma, IT, and services. He holds a master's degree in economics from Aarhus University.
Progenity: Sean Lavin
Progenity announced that Sean Lavin has been appointed as VP of business development, strategy, and investor relations. He will work with the company's senior management on strategy, business development, investor outreach, and shareholder value creation. He runs his own firm, Alpha Lavin Advisors, that focuses on value creation in the medical device and diagnostic sectors. Lavin previously served as a managing director in equity research at BTIG and Lazard Capital Markets covering these sectors. He joined Lazard in 2008 as the senior medical technology and diagnostic analyst and moved to BTIG as a senior healthcare analyst in 2013.
For additional recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.